Cassidy Rose Doyle

Cassidy Doyle practices at MEDHERO Urgent Care - San Clemente in San Clemente, California.

Cassidy Doyle's NPI, 1861126286, was assigned on July 12, 2022. Cassidy Doyle holds California license PA62851.

Cassidy Doyle's primary practice is MEDHERO Urgent Care - San Clemente, at 905 Calle Amanecer, San Clemente, CA 92673. The practice phone is (949) 207-3603.

Cassidy Doyle's primary practice is MEDHERO Urgent Care - San Clemente in San Clemente, California. The medical group on file is MEDHERO. Dmand AI also links Cassidy Doyle to 2 more medical groups and 1 group practice or clinic, each named with a free account. Cassidy Doyle's employer is on file too: an urgent care center.

Dmand AI tracks the electronic health record (EHR) system at each site where Cassidy Doyle practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Cassidy Doyle's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Cassidy Doyle is licensed in California.

CMS data shows 604 Medicare services from Cassidy Doyle across 12 procedure codes in 2024, for 284 Medicare patients. Medicare paid $30,186 for them. Every service was in an office.

CMS counts 284 Medicare patients who saw Cassidy Doyle in 2024. The largest group is 65 to 74, with 136 patients. 73% of them have high cholesterol, and 60% have high blood pressure. Their average risk score is 0.89, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Cassidy Doyle's median patient age at 39, with 56% women.

In 2024, Cassidy Doyle wrote 263 Medicare Part D claims for 186 patients. 91% of them were for generic drugs. CMS names the drug for 144 of them, across 7 drugs with 11 or more claims each, at $1,579 in total drug cost.

Cassidy Doyle accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 7 general payments to Cassidy Doyle from 2 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $208.